Psyched Wellness Announces Findings from an Ongoing Study with the National Research Council of Canada

Toronto, Ontario--(Newsfile Corp. - July 26, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce the preliminary data from tests completed by the National Research Council of Canada (NRC).

One of the primary immune cells in the brain are the microglia, which facilitate neurodevelopment and neurodegeneration. Recent work investigated how AME-1 extract could modify microglial functions. Microglia respond to a variety of stimuli, including lipopolysaccharides found in the cell walls of bacteria (LPS), viral components (such as poly I:C nucleotides) and inflammatory cytokines such as tumor necrosis factor (TNF). In a recent study, researchers stimulated human microglial cells with LPS, poly I:C and TNF in the presence of AME-1 to determine if AME-1 could modify how microglia respond to these common stimulants.

The researchers found that a specific nucleotide, poly I:C, caused the microglia to be more activated than normal and produce important immune mediators. This could potentially indicate that AME-1 boosts the antiviral immune response in the brain, perhaps protecting brain tissue from viral infection.

AME-1 had no significant effect on how microglia respond to LPS and TNF. However, AME-1 potentiated poly I:C activation of microglial cells, resulting in greater production of the chemokine, IL-8. The chemokine IL-8 is a protein that attracts immune cells to the site of infection. Preliminary research has shown that this process may be mediated by AME-1 upregulation of the Toll-Like Receptor -3, which is the receptor that mediates microglial responses to poly I:C. Further experiments will examine how AME-1 upregulates TLR3 by microglial cells and how this could be contributing to the increased responses to poly I:C, which may contribute to the anti-viral immune response in the brain and thus reduce viral infection.

This work is preliminary, and more work is needed to further investigate the potential benefits from the natural product AME-1.

"This additional preliminary evidence of the investigative study is revealing key functional properties of the AME-1 extract. This Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach to help understand the functional neuroprotective property of AME-1," says Brian Tancowny, scientific advisor to Psyched Wellness.

"When it comes to the Amanita Muscaria mushroom, we are the first in many fields of research," says David Shisel, the company's COO. "Our extract, AME-1 provides us with the opportunity to do multiple studies and the more we examine the extract, the more we understand this incredible powerful mushroom. This is just the tip of the iceberg and we plan to continue researching and understanding its powers along the way."

Psyched Wellness is launching its first AME-1 product, Calm, in the coming months. Calm is currently available for preorder.

To preorder Calm, visit shop.psyched-wellness.com.

The NRC specializes in providing vital scientific and technological services to the research and industrial communities of Canada and was hired by Psyched Wellness to provide expertise in biomedical nanotechnology. The results of the research belong to Psyched, and the NRC does not endorse the findings or Psyched products.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131917

info